• Xintela published peer-reviewed Phase I/IIa results for XSTEM in knee osteoarthritis in the journal Cartilage; results were previously presented in September 2025.
• The study showed the treatment was well tolerated, with no serious treatment-related safety issues reported.
• Patients reported reduced knee pain and improved joint function, supporting a potential disease-modifying effect.
• The highest dose showed sustained improvements in cartilage and bone tissue quality for up to two years, with signs of slowing cartilage breakdown.
• Publication increases visibility of the dataset for potential partners, strengthening the investment case for further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xintela AB published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.